Sanofi Ends Maze Licensing Deal Over FTC Concerns
Sanofi has terminated its global licensing agreement with Maze Therapeutics for Pompe disease treatment, citing issues related to FTC regulations.
Topic
licensing agreement
A collection of 1 issue